Blake Williamson
Ophthalmology · Baton Rouge, LANPI 1720370067
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $276,459 of the $443,285 with a category attached, or 62.4%. 36 manufacturers reported payments, led by Glaukos Corporation at 26.6% of the total. Reporting peaked in 2019 at $104,787 and has fallen 61.9% since, to $39,873 in 2025. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 613 payments — averaging $723.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$118K
- Johnson & Johnson Surgical Vision, Inc.$107K
- Eyevance Pharmaceuticals LLC$55K
- Sight Sciences, Inc.$51K
- AbbVie$46K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$15K
- plus $51K from 30 others
Across 8 payments — averaging $5434.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$21K
- Johnson & Johnson Surgical Vision, Inc.$18K
- Novartis$4K
What the payments were for
- Consulting fees$276,45962%
- Speaking & faculty fees$124,12728%
- Travel & lodging$25,0146%
- Food & beverage$17,4884%
- Gifts$450%
- Entertainment$1520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tobradex ST$55,139
- iStent inject Trabecular Micro-Bypass Stent System$50,868
- One Series Ultra$48,525
- Unfolder Silver$48,525
- Whitestar Signature$48,525
- VUITY$40,734
- OMNI(R) SURGICAL SYSTEM (US)$26,102
- OMNI$23,907
- Catalys Laser System$23,497
- iStent inject W$19,160
- One Series Ultra IOL Delivery System$18,000
- Unfolder IOL Delivery Systems$18,000
- Whitestar Phacoemulsficiation System$18,000
- ENVISTA TORIC$14,415
- iDose$14,000
- Ahmed Glaucoma Valve$13,179
- Kahook Dual Blade$13,179
- Tecnis Multifocal Family of 1-piece IOLS$10,863
- iStent Trabecular Micro-Bypass Stent System$8,565
- Travoprost Intraocular Implant - iDose$8,550
How this compares
$443,285 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 483 | $15,200 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $9,440 |
| RestasisCyclosporine | 11 | $8,734 |
| IlevroNepafenac | 11 | $4,134 |
| Alphagan PBrimonidine Tartrate | 16 | $3,495 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $2,535 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 19 | $2,423 |
| Latanoprost | 193 | $1,248 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 28 | $477 |
| Ciprofloxacin Hcl | 31 | $411 |
| Timolol Maleate | 23 | $174 |
| Brimonidine Tartrate | 20 | $121 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan, Restasis, Alphagan P | $46,434 | $21,67048 claims |
| NovartisIlevro | $529 | $4,13411 claims |
| AlconSimbrinza | $994 | $2,53512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Baton Rouge
- Charles WilliamsonBaton Rouge$16K
- David FargasonBaton Rouge$6K
- Philip EhrlichBaton Rouge$6K
- Daniel NelsonBaton Rouge$6K
- Michael MorganBaton Rouge$6K
- Thomas StuckeyBaton Rouge$6K
- George FivgasBaton Rouge$6K
- Devin TranBaton Rouge$5K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.